• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Selection of PD1/PD-L1 X-Aptamers.PD1/PD-L1 X-适体的筛选。
Biochimie. 2018 Feb;145:125-130. doi: 10.1016/j.biochi.2017.09.006. Epub 2017 Sep 11.
2
Selection of threose nucleic acid aptamers to block PD-1/PD-L1 interaction for cancer immunotherapy.筛选阻断 PD-1/PD-L1 相互作用的 threose 核酸适体用于癌症免疫治疗。
Chem Commun (Camb). 2020 Dec 4;56(93):14653-14656. doi: 10.1039/d0cc06032a. Epub 2020 Nov 6.
3
[Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].[PD-1/PD-L1免疫检查点抑制剂在胸段癌症中的疗效及PD-L1检测]
Ann Pathol. 2017 Feb;37(1):61-78. doi: 10.1016/j.annpat.2016.12.009. Epub 2017 Feb 3.
4
Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect.抗 PD-L1 DNA 适体拮抗 PD-1/PD-L1 的相互作用并具有抗肿瘤作用。
J Mater Chem B. 2021 Jan 28;9(3):746-756. doi: 10.1039/d0tb01668c.
5
X-aptamers targeting Thy-1 membrane glycoprotein in pancreatic ductal adenocarcinoma.针对胰腺导管腺癌中 Thy-1 膜糖蛋白的 X-适体。
Biochimie. 2021 Feb;181:25-33. doi: 10.1016/j.biochi.2020.11.018. Epub 2020 Nov 23.
6
Aptamer-assisted phage display: enhancing checkpoint inhibition with a peptide and an aptamer targeting distinct sites on a single PD-L1 protein.适体辅助噬菌体展示:利用靶向单个PD-L1蛋白上不同位点的肽和适体增强检查点抑制作用。
Chem Commun (Camb). 2024 Jul 18;60(59):7570-7573. doi: 10.1039/d4cc02132k.
7
PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials.PD1/PD-L1 靶向治疗晚期软组织肉瘤的疗效:两项 II 期临床试验的汇总分析。
J Hematol Oncol. 2020 May 19;13(1):55. doi: 10.1186/s13045-020-00891-5.
8
Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.程序性细胞死亡配体 1 截断值与切除的胰腺导管腺癌患者疾病特异性生存时间降低相关。
BMC Cancer. 2017 Sep 5;17(1):618. doi: 10.1186/s12885-017-3634-5.
9
Development and Evaluation of Novel Aptamers Specific for Human PD1 Using Hybrid Systematic Evolution of Ligands by Exponential Enrichment Approach.利用杂交指数富集配体系统进化技术(SELEX)开发并评估针对人 PD1 的新型适体。
Immunol Invest. 2020 Jul;49(5):535-554. doi: 10.1080/08820139.2020.1744639. Epub 2020 May 19.
10
An optimized protocol for the in vitro generation and functional analysis of human PD1/PD-L1 signal.一种用于人PD1/PD-L1信号体外生成及功能分析的优化方案。
J Recept Signal Transduct Res. 2018 Feb;38(1):31-36. doi: 10.1080/10799893.2017.1414843. Epub 2017 Dec 18.

引用本文的文献

1
Aptamer based immunotherapy: a potential solid tumor therapeutic.基于适配体的免疫疗法:一种潜在的实体瘤治疗方法。
Front Immunol. 2025 Feb 17;16:1536569. doi: 10.3389/fimmu.2025.1536569. eCollection 2025.
2
Development of selective ssDNA micro-probe for PD1 detection as a novel strategy for cancer imaging.开发用于 PD1 检测的选择性 ssDNA 微探针作为癌症成像的新策略。
Sci Rep. 2024 Nov 19;14(1):28652. doi: 10.1038/s41598-024-74891-7.
3
bioTCIs: Middle-to-Macro Biomolecular Targeted Covalent Inhibitors Possessing Both Semi-Permanent Drug Action and Stringent Target Specificity as Potential Antibody Replacements.生物 TCIs:具有半永久药物作用和严格靶标特异性的中到大分子生物靶向共价抑制剂,可作为潜在的抗体替代品。
Int J Mol Sci. 2023 Feb 9;24(4):3525. doi: 10.3390/ijms24043525.
4
Strategies for developing long-lasting therapeutic nucleic acid aptamer targeting circulating protein: The present and the future.开发针对循环蛋白的长效治疗性核酸适配体的策略:现状与未来。
Front Cell Dev Biol. 2022 Nov 1;10:1048148. doi: 10.3389/fcell.2022.1048148. eCollection 2022.
5
Cancer immunomodulation using bispecific aptamers.使用双特异性适体进行癌症免疫调节。
Mol Ther Nucleic Acids. 2022 Jan 10;27:894-915. doi: 10.1016/j.omtn.2022.01.008. eCollection 2022 Mar 8.
6
Synthesis and characterization of novel ssDNA X-aptamers targeting Growth Hormone Releasing Hormone (GHRH).靶向生长激素释放激素(GHRH)的新型单链DNA X-适配体的合成与表征
PLoS One. 2022 Jan 21;17(1):e0260144. doi: 10.1371/journal.pone.0260144. eCollection 2022.
7
The Roles of Sclerostin in Immune System and the Applications of Aptamers in Immune-Related Research.骨硬化蛋白在免疫系统中的作用及适体在免疫相关研究中的应用。
Front Immunol. 2021 Feb 25;12:602330. doi: 10.3389/fimmu.2021.602330. eCollection 2021.
8
X-aptamers targeting Thy-1 membrane glycoprotein in pancreatic ductal adenocarcinoma.针对胰腺导管腺癌中 Thy-1 膜糖蛋白的 X-适体。
Biochimie. 2021 Feb;181:25-33. doi: 10.1016/j.biochi.2020.11.018. Epub 2020 Nov 23.
9
High JAK2 Protein Expression Predicts a Poor Prognosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma.高 JAK2 蛋白表达预示可切除胰腺导管腺癌患者预后不良。
Dis Markers. 2020 Sep 21;2020:7656031. doi: 10.1155/2020/7656031. eCollection 2020.
10
Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma.适配体:用于胰腺导管腺癌的新型靶向治疗平台。
Radiat Oncol. 2020 Aug 5;15(1):189. doi: 10.1186/s13014-020-01624-1.

本文引用的文献

1
Ipilimumab-Based
 Therapy: Consensus Statement From the Faculty of the Melanoma Nursing Initiative on Managing Adverse Events With Ipilimumab Monotherapy and Combination Therapy With Nivolumab.基于伊匹木单抗的治疗:黑色素瘤护理倡议组织教员关于伊匹木单抗单药治疗及与纳武单抗联合治疗不良事件管理的共识声明
Clin J Oncol Nurs. 2017 Aug 1;21(4 Suppl):30-41. doi: 10.1188/17.CJON.S4.30-41.
2
X-Aptamer Selection and Validation.X适配体的筛选与验证。
Methods Mol Biol. 2017;1632:151-174. doi: 10.1007/978-1-4939-7138-1_10.
3
Risk of treatment-related mortality in cancer patients treated with ipilimumab: A systematic review and meta-analysis.接受伊匹单抗治疗的癌症患者的治疗相关死亡风险:一项系统评价和荟萃分析。
Eur J Cancer. 2017 Sep;83:71-79. doi: 10.1016/j.ejca.2017.06.021. Epub 2017 Jul 15.
4
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.纳武单抗联合伊匹木单抗治疗转移性肾细胞癌的安全性和疗效:CheckMate 016研究
J Clin Oncol. 2017 Dec 1;35(34):3851-3858. doi: 10.1200/JCO.2016.72.1985. Epub 2017 Jul 5.
5
Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.针对免疫检查点分子的抗体恢复了肝癌浸润 T 细胞的功能。
Gastroenterology. 2017 Oct;153(4):1107-1119.e10. doi: 10.1053/j.gastro.2017.06.017. Epub 2017 Jun 23.
6
Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1.通过瞬时诱导的蛋白质状态和 PD-L1 二聚化来抑制程序性细胞死亡-1/程序性死亡配体 1(PD-1/PD-L1)相互作用的小分子抑制剂。
J Med Chem. 2017 Jul 13;60(13):5857-5867. doi: 10.1021/acs.jmedchem.7b00293. Epub 2017 Jun 23.
7
Anti-PD-1/PD-L1 antibody versus conventional chemotherapy for previously-treated, advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.抗程序性死亡蛋白1/程序性死亡配体1抗体与传统化疗用于既往治疗过的晚期非小细胞肺癌:一项随机对照试验的荟萃分析
J Thorac Dis. 2017 Mar;9(3):655-665. doi: 10.21037/jtd.2017.03.104.
8
In vivo IL-4 prevents allo-antigen driven CD8 CTL development.体内白细胞介素-4可阻止同种抗原驱动的CD8细胞毒性T淋巴细胞的发育。
Clin Immunol. 2017 Jul;180:11-24. doi: 10.1016/j.clim.2017.03.008. Epub 2017 Mar 27.
9
Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.利用免疫系统对抗白血病:急性髓系白血病的单克隆抗体与检查点策略
Adv Exp Med Biol. 2017;995:73-95. doi: 10.1007/978-3-319-53156-4_4.
10
Mechanisms of Resistance to Immune Checkpoint Antibodies.免疫检查点抗体耐药机制。
Handb Exp Pharmacol. 2018;249:109-128. doi: 10.1007/164_2017_11.

PD1/PD-L1 X-适体的筛选。

Selection of PD1/PD-L1 X-Aptamers.

机构信息

Institute of Molecular Medicine, University of Texas Health Science Center at Houston, 1825 Pressler Street, Houston, TX, 77030, USA.

AM Biotechnologies, LLC, 12521 Gulf Freeway, Houston, TX, 77034, USA.

出版信息

Biochimie. 2018 Feb;145:125-130. doi: 10.1016/j.biochi.2017.09.006. Epub 2017 Sep 11.

DOI:10.1016/j.biochi.2017.09.006
PMID:28912094
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5794648/
Abstract

Specific, chemically modified aptamers (X-Aptamers) were identified against two immune checkpoint proteins, recombinant Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1). Selections were performed using a bead-based X-Aptamer (XA) library containing several different amino acid functional groups attached to dU at the 5-position. The binding affinities and specificities of the selected XA-PD1 and XA-PDL1 were validated by hPD-1 and hPD-L1 expression cells, as well as by binding to human pancreatic ductal adenocarcinoma tissue. The selected PD1 and PDL1 XAs can mimic antibody functions in in vitro assays.

摘要

针对两种免疫检查点蛋白,即重组程序性死亡受体 1(PD-1)和程序性死亡配体 1(PD-L1),鉴定了特定的、化学修饰的适体(X-适体)。选择是使用一种基于珠子的 X-适体(XA)文库进行的,该文库包含了几种不同的氨基酸官能团,连接在 dU 的 5 位上。所选 XA-PD1 和 XA-PDL1 的结合亲和力和特异性通过 hPD-1 和 hPD-L1 表达细胞以及与人胰腺导管腺癌组织的结合进行了验证。所选的 PD1 和 PDL1 XAs 可以在体外实验中模拟抗体的功能。